VOYA Investment Management
VKTX icon

VOYA Investment Management’s Viking Therapeutics VKTX Stock Holding History

VOYA Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Buy
65,150
+36,079
+124% +$1.17M ﹤0.01% 1133
2026
Q1 		$946K Buy
29,071
+3,281
+13% +$105K ﹤0.01% 1473
2025
Q4 		$907K Sell
25,790
-1,007
-4% -$35.7K ﹤0.01% 1506
2025
Q3 		$704K Sell
26,797
-303,855
-92% -$9.06M ﹤0.01% 1613
2025
Q2 		$8.76M Sell
330,652
-35,727
-10% -$940K 0.01% 769
2025
Q1 		$8.85M Sell
366,379
-23,761
-6% -$751K 0.01% 769
2024
Q4 		$15.7M Sell
390,140
-283,999
-42% -$16.2M 0.02% 618
2024
Q3 		$42.7M Buy
674,139
+51,734
+8% +$3.04M 0.04% 368
2024
Q2 		$33M Sell
622,405
-454,283
-42% -$29.8M 0.03% 402
2024
Q1 		$88.3M Buy
1,076,688
+1,038,248
+2,701% +$46.2M 0.09% 245
2023
Q4 		$715K Sell
38,440
-90
-0.2% -$1.18K ﹤0.01% 1876
2023
Q3 		$427K Buy
38,530
+465
+1% +$6.65K ﹤0.01% 2123
2023
Q2 		$617K Buy
+38,065
New +$797K ﹤0.01% 1967
2022
Q2 		– Sell
-27,389
Closed -$82K – 2896
2022
Q1 		$82K Hold
27,389
– – ﹤0.01% 2539
2021
Q4 		$126K Sell
27,389
-964
-3% -$5.4K ﹤0.01% 2628
2021
Q3 		$178K Hold
28,353
– – ﹤0.01% 2606
2021
Q2 		$170K Sell
28,353
-1,981
-7% -$11.8K ﹤0.01% 2651
2021
Q1 		$192K Buy
30,334
+1,630
+6% +$11.5K ﹤0.01% 2553
2020
Q4 		$162K Buy
28,704
+5,325
+23% +$32.3K ﹤0.01% 2484
2020
Q3 		$136K Hold
23,379
– – ﹤0.01% 2276
2020
Q2 		$169K Sell
23,379
-8,746
-27% -$58.1K ﹤0.01% 2211
2020
Q1 		$150K Hold
32,125
– – ﹤0.01% 2226
2019
Q4 		$258K Buy
32,125
+5,338
+20% +$38.9K ﹤0.01% 2255
2019
Q3 		$184K Hold
26,787
– – ﹤0.01% 2265
2019
Q2 		$222K Buy
26,787
+1,716
+7% +$14.7K ﹤0.01% 2247
2019
Q1 		$249K Hold
25,071
– – ﹤0.01% 2152
2018
Q4 		$192K Buy
25,071
+4,842
+24% +$57.9K ﹤0.01% 2233
2018
Q3 		$352K Buy
20,229
+3,298
+19% +$39.2K ﹤0.01% 2061
2018
Q2 		$161K Buy
+16,931
New +$113K ﹤0.01% 2422

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

VOYA Investment Management's VKTX Position: Q2 2026 in Review

VOYA Investment Management increased its Viking Therapeutics (VKTX) stake by 124% in Q2 2026, buying an estimated $1.17M and bringing the position to 65,150 shares worth $2.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1133.

VOYA Investment Management first reported a position in VKTX in Q2 2018 and has held it in 29 quarters since. The position peaked at $88.3M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • VOYA Investment Management held 65,150 shares of Viking Therapeutics worth $2.54M as of Q2 2026.
  • VOYA Investment Management bought 36,079 Viking Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Viking Therapeutics made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #1133 holding.
  • VOYA Investment Management first reported a position in Viking Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • VOYA Investment Management's Viking Therapeutics position peaked at $88.3M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.